Physician profile
Paul E Dudley
NPI 1194721332
$8,567.06
in general payments reported to CMS, 2019-2025
51 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $1,055 · 2021: $1,212 · 2022: $1,214 · 2023: $943 · 2024: $1,310 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,907.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,115.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $948.10 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $828.36 | 2019-2025 | Evenity, Prolia, Otezla |
| Astellas Pharma US INC | $657.03 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $454.97 | 2019-2025 | Airsupra, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $399.79 | 2019-2025 | Camzyos, Eliquis |
| Medicure Pharma INC. | $371.32 | 2020 | |
| Pfizer INC. | $340.55 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $302.89 | 2022-2025 | |
| Glaxosmithkline, LLC. | $265.33 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $248.31 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $225.98 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.54 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.42 | 2021-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $170.59 | 2019-2025 | Austedo Xr |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dudley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.